Ovid Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing small molecule therapeutics for brain disorders characterized by neuronal hyperexcitability. Headquartered in New York, the company's research and development efforts are primarily focused on severe neurological and neuropsychiatric conditions, including drug-resistant epilepsies, tuberous sclerosis complex, infantile spasms, and psychoses.
As a clinical-stage entity, Ovid does not yet generate revenue from commercial product sales; its near-term revenue is derived entirely from licensing agreements, royalties, and strategic collaborations. The company's business model relies on advancing its proprietary pipeline through clinical trials while leveraging partnerships for funding and co-development.
Ovid's pipeline is anchored by its focus on small molecule compounds that modulate specific biological targets in the brain. Key clinical programs include OV329, a next-generation GABA-aminotransferase (GABA-AT) inhibitor designed to provide a safer and more potent alternative to existing treatments for refractory epilepsies. Additionally, Ovid is pioneering a portfolio of potassium-chloride cotransporter 2 (KCC2) direct activators, including the intravenous candidate OV350 and the oral candidate OV4071, which are being evaluated for their potential to treat psychoses and other central nervous system disorders. By focusing exclusively on small molecules rather than complex biologics, Ovid aims to offer versatile dosing options, including oral pills and injections, to improve patient compliance and manufacturing scalability.
